Latest News and Press Releases

First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated Evidence for generation of virus-specific effector and memory CD8+ T cells Data reinforce findings from trial of...

ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through...

A Emergex e o IBMP do Brasil irão cofinanciar estudos de Fase II e Fase III da Emergex no Brasil, para medicamentos experimentais para o tratamento da Febre da Dengue e do Betacoronavírus relacionados...

Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic candidates in Brazil, with potential to...

naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+...